Doxifluridine

An active agent in advanced gastrointestinal cancer

M. Di Bartolomeo, E. Bajetta, L. Somma, R. Buzzoni

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Background: The results of the use of chemotherapy in patients with advanced gastrointestinal malignancies have been disappointing. Complete responses are rare, and even partial responses are generally few with no benefit on survival. Since its introduction in clinical trials more than 30 years ago, fluorouracil has remained the most effective single agent in the treatment of these diseases. Doxifluridine is a new fluoropyrimidine derivative, that is converted into fluorouracil, its active component. Experimental data confirm cytotoxic selectivity for human tumor cells. Methods: Three trials have been conducted at the Istituto Nazionale Tumori of Milan, to evaluate the tolerability and efficacy of doxifluridine administered endovenously or orally in patients affected by different gastrointestinal neoplasms. The data will be discussed. Conclusions: Our results indicate that doxifluridine may be superior to fluorouracil, the biochemical modulator as folinic acid seems to enhance its activity in colorectal patients. The oral schedule is feasible for home treatment.

Original languageEnglish
Pages (from-to)147-150
Number of pages4
JournalTumori
Volume81
Issue number3 SUPPL.
Publication statusPublished - 1995

Fingerprint

Gastrointestinal Neoplasms
Fluorouracil
Leucovorin
Neoplasms
Appointments and Schedules
Clinical Trials
Drug Therapy
Survival
Therapeutics
doxifluridine

Keywords

  • chemotherapy
  • doxifluridine
  • gastrointestinal cancer

ASJC Scopus subject areas

  • Cancer Research

Cite this

Doxifluridine : An active agent in advanced gastrointestinal cancer. / Di Bartolomeo, M.; Bajetta, E.; Somma, L.; Buzzoni, R.

In: Tumori, Vol. 81, No. 3 SUPPL., 1995, p. 147-150.

Research output: Contribution to journalArticle

Di Bartolomeo, M, Bajetta, E, Somma, L & Buzzoni, R 1995, 'Doxifluridine: An active agent in advanced gastrointestinal cancer', Tumori, vol. 81, no. 3 SUPPL., pp. 147-150.
Di Bartolomeo, M. ; Bajetta, E. ; Somma, L. ; Buzzoni, R. / Doxifluridine : An active agent in advanced gastrointestinal cancer. In: Tumori. 1995 ; Vol. 81, No. 3 SUPPL. pp. 147-150.
@article{c9d058e0a9fd46f7bcc7f9f1010611e7,
title = "Doxifluridine: An active agent in advanced gastrointestinal cancer",
abstract = "Background: The results of the use of chemotherapy in patients with advanced gastrointestinal malignancies have been disappointing. Complete responses are rare, and even partial responses are generally few with no benefit on survival. Since its introduction in clinical trials more than 30 years ago, fluorouracil has remained the most effective single agent in the treatment of these diseases. Doxifluridine is a new fluoropyrimidine derivative, that is converted into fluorouracil, its active component. Experimental data confirm cytotoxic selectivity for human tumor cells. Methods: Three trials have been conducted at the Istituto Nazionale Tumori of Milan, to evaluate the tolerability and efficacy of doxifluridine administered endovenously or orally in patients affected by different gastrointestinal neoplasms. The data will be discussed. Conclusions: Our results indicate that doxifluridine may be superior to fluorouracil, the biochemical modulator as folinic acid seems to enhance its activity in colorectal patients. The oral schedule is feasible for home treatment.",
keywords = "chemotherapy, doxifluridine, gastrointestinal cancer",
author = "{Di Bartolomeo}, M. and E. Bajetta and L. Somma and R. Buzzoni",
year = "1995",
language = "English",
volume = "81",
pages = "147--150",
journal = "Tumori",
issn = "0300-8916",
publisher = "SAGE Publications Ltd",
number = "3 SUPPL.",

}

TY - JOUR

T1 - Doxifluridine

T2 - An active agent in advanced gastrointestinal cancer

AU - Di Bartolomeo, M.

AU - Bajetta, E.

AU - Somma, L.

AU - Buzzoni, R.

PY - 1995

Y1 - 1995

N2 - Background: The results of the use of chemotherapy in patients with advanced gastrointestinal malignancies have been disappointing. Complete responses are rare, and even partial responses are generally few with no benefit on survival. Since its introduction in clinical trials more than 30 years ago, fluorouracil has remained the most effective single agent in the treatment of these diseases. Doxifluridine is a new fluoropyrimidine derivative, that is converted into fluorouracil, its active component. Experimental data confirm cytotoxic selectivity for human tumor cells. Methods: Three trials have been conducted at the Istituto Nazionale Tumori of Milan, to evaluate the tolerability and efficacy of doxifluridine administered endovenously or orally in patients affected by different gastrointestinal neoplasms. The data will be discussed. Conclusions: Our results indicate that doxifluridine may be superior to fluorouracil, the biochemical modulator as folinic acid seems to enhance its activity in colorectal patients. The oral schedule is feasible for home treatment.

AB - Background: The results of the use of chemotherapy in patients with advanced gastrointestinal malignancies have been disappointing. Complete responses are rare, and even partial responses are generally few with no benefit on survival. Since its introduction in clinical trials more than 30 years ago, fluorouracil has remained the most effective single agent in the treatment of these diseases. Doxifluridine is a new fluoropyrimidine derivative, that is converted into fluorouracil, its active component. Experimental data confirm cytotoxic selectivity for human tumor cells. Methods: Three trials have been conducted at the Istituto Nazionale Tumori of Milan, to evaluate the tolerability and efficacy of doxifluridine administered endovenously or orally in patients affected by different gastrointestinal neoplasms. The data will be discussed. Conclusions: Our results indicate that doxifluridine may be superior to fluorouracil, the biochemical modulator as folinic acid seems to enhance its activity in colorectal patients. The oral schedule is feasible for home treatment.

KW - chemotherapy

KW - doxifluridine

KW - gastrointestinal cancer

UR - http://www.scopus.com/inward/record.url?scp=0029127078&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0029127078&partnerID=8YFLogxK

M3 - Article

VL - 81

SP - 147

EP - 150

JO - Tumori

JF - Tumori

SN - 0300-8916

IS - 3 SUPPL.

ER -